Comprehensive Review on PARP Inhibitors in Ovarian Cancer: A Breakthrough in Diagnostic and Therapeutic Approaches

Ovarian cancer, a challenging malignancy often diagnosed in advanced stages, has witnessed a transformative shift in treatment paradigms with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors. These agents that target DNA repair pathways through synthetic lethality have demonstrated remarkable efficacy across various ovarian cancer subtypes. Notably, olaparib, niraparib and rucaparib have emerged as pivotal players in this therapeutic revolution. This review explores the fundamental role of these three PARP inhibitors and gives an overview of the therapeutic landscape and the role of PARP inhibitors in the future including combination therapy.